Skip to main content
. 2015 Nov 27;89(6):295–299. doi: 10.4174/astr.2015.89.6.295

Table 3. Treatment modalities for mixed MALT and DLBCL patients.

graphic file with name astr-89-295-i003.jpg

MALT, mucosa-associated lymphoid tissue; DLBCL, diffuse large B-cell lymphoma; R-CHOP, rituximab with cyclophosphamide, doxorubicin, cyclophosphamide and prednisone; RT, radiotherapy.